By integrating two statistical methods, we found that male patients in the EGFR-TKI treatment group had a poorer prognosis, indicating that gender differences in NSCLC patients should be considered, particularly for male patients receiving EGFR-TKI treatment or those at specific clinical stages, as their prognosis may be worse. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.